Xuemei Huang

Xuemei Huang, M.D., Ph.D.
Associate Professor & Vice Chair for Research, Department of Neurology at Pennsylvania State University
500 University Drive Hershey PA 17033
Educational Details: 

2002 - Neurology Research, University of North Carolina School of Medicine-Fellowship

2001 - Movement Disorders, Emory University Medical Center (Georgia)-Fellowship

2000 - Neurology, University of North Carolina School of Medicine-Residency,

1997 - Medicine, University of Washington School of Medicine-Internship

1987 - Beijing Medical University-M.D.

Selected Publications: 
Lewis MM, Galley S, Johnson S, Stevenson J, Huang X, McKeown MJ. The role of the cerebellum in the pathophysiology of Parkinson's disease. Can J Neurol Sci. 2013 May; 40(3):299-306.

Sterling NW, Du G, Lewis MM, Dimaio C, Kong L, Eslinger PJ, Styner M, Huang X. Striatal shape in Parkinson's disease. Neurobiol Aging. 2013 Nov; 34(11):2510-6.

Park J, Lewis MM, Huang X, Latash ML. Effects of olivo-ponto-cerebellar atrophy (OPCA) on finger interaction and coordination. Clin Neurophysiol. 2013 May; 124(5):991-8.

Lewis MM, Du G, Kidacki M, Patel N, Shaffer ML, Mailman RB, Huang X. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging. 2013 May; 34(5):1497-503.

Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M, Yang QX, Huang X. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord. 2012 Nov; 27(13):1636-43.

Park J, Wu YH, Lewis MM, Huang X, Latash ML. Changes in multifinger interaction and coordination in Parkinson's disease. J Neurophysiol. 2012 Aug 1; 108(3):915-24.

Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, Huang X. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. PLoS One. 2012; 7(4):e35397.

Huang X, Mahoney JM, Lewis MM. Both coordination and symmetry of arm swing are reduced in Parkinson's disease. Gait Posture. 2012 Mar; 35(3):373-7.

Gao J, Huang X, Park Y, Hollenbeck A, Chen H. An exploratory study on CLU, CR1 and PICALM and Parkinson disease. PLoS One. 2011; 6(8):e24211.

Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One. 2011; 6(8):e22854.

Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, Mailman RB, Chen H. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging. 2011 Nov; 32(11):2106.e1-6.

Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord. 2011 Aug 1; 26(9):1627-32.

Gao J, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, Chen H. Daytime napping, nighttime sleeping, and Parkinson disease. Am J Epidemiol. 2011 May 1; 173(9):1032-8.

Lewis MM, Du G, Sen S, Kawaguchi A, Truong Y, Lee S, Mailman RB, Huang X. Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease. Neuroscience. 2011 Mar 17; 177:230-9.

Brenner SR, Chen H, Kamel F, Park Y, Hollenbeck A, Huang X. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010 Aug 10; 75(6):574-5; author reply 574.

Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, Chen H. Physical activities and future risk of Parkinson disease. Neurology. 2010 Jul 27; 75(4):341-8.

Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010 Mar 16; 74(11):878-84.

Huang X, Chen H, Petrovitch H, Mailman R, Ross W. Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent? Mov Disord. 2010 Jan 15; 25(1):137.

Sen S, Kawaguchi A, Truong Y, Lewis MM, Huang X. Dynamic changes in cerebello-thalamo-cortical motor circuitry during progression of Parkinson's disease. Neuroscience. 2010 Mar 17; 166(2):712-9.

Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, Li Y, Barbero X, Gouttard S, McKeown MJ, Mailman RB, Huang X. Asymmetrical lateral ventricular enlargement in Parkinson's disease. Eur J Neurol. 2009 Apr; 16(4):475-81.

Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May 15; 23(7):1013-8.

McKeown MJ, Uthama A, Abugharbieh R, Palmer S, Lewis M, Huang X. Shape (but not volume) changes in the thalami in Parkinson disease. BMC Neurol. 2008; 8:8.

Huang X, Lee YZ, McKeown M, Gerig G, Gu H, Lin W, Lewis MM, Ford S, Tröster AI, Weinberger DR, Styner M. Asymmetrical ventricular enlargement in Parkinson's disease. Mov Disord. 2007 Aug 15; 22(11):1657-60.

McKeown MJ, Li J, Huang X, Lewis MM, Rhee S, Young Truong KN, Wang ZJ. Local linear discriminant analysis (LLDA) for group and region of interest (ROI)-based fMRI analysis. Neuroimage. 2007 Sep 1; 37(3):855-65.

Lewis MM, Slagle CG, Smith AB, Truong Y, Bai P, McKeown MJ, Mailman RB, Belger A, Huang X. Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries. Neuroscience. 2007 Jun 15; 147(1):224-35.

George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007 Jul; 93(1-3):42-50.

Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord. 2007 Feb 15; 22(3):377-81.

Mailman RB, Huang X. Dopamine receptor pharmacology. Handb Clin Neurol. 2007; 83:77-105.

Lewis MM, Huang X, Nichols DE, Mailman RB. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets. 2006 Jun; 5(3):345-53.

Huang X, Chen P, Kaufer DI, Tröster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006 Feb; 63(2):189-93.

Huang X, Chen PC, Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004 Jun 22; 62(12):2198-202.

Mailman R, Huang X, Nichols DE. Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs. 2001 Nov; 2(11):1582-91.

Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB. D1 dopamine receptors. Int Rev Neurobiol. 2001; 48:65-139.

Cozzi NV, Frescas S, Marona-Lewicka D, Huang X, Nichols DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav. 1998 Mar; 59(3):709-15.

Nichols DE, Monte A, Huang X, Marona-Lewicka D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav Brain Res. 1996; 73(1-2):117-9.

Oberlender R, Ramachandran PV, Johnson MP, Huang X, Nichols DE. Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. J Med Chem. 1995 Sep 1; 38(18):3593-601.

Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem. 1994 Dec 9; 37(25):4346-51.

Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol Biochem Behav. 1994 Mar; 47(3):667-73.

Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE. Lysergamides revisited. NIDA Res Monogr. 1994; 146:52-73.

Sprague JE, Huang X, Kanthasamy A, Nichols DE. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci. 1994; 55(15):1193-8.

Huang X, Nichols DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol. 1993 Jul 20; 238(2-3):291-6.

Nichols DE, Marona-Lewicka D, Huang X, Johnson MP. Novel serotonergic agents. Drug Des Discov. 1993; 9(3-4):299-312.

Huang X, Marona-Lewicka D, Nichols DE. p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol. 1992 Dec 8; 229(1):31-8.

Tomaszewski Z, Johnson MP, Huang X, Nichols DE. Benzofuran bioisosteres of hallucinogenic tryptamines. J Med Chem. 1992 May 29; 35(11):2061-4.

Oberlender R, Pfaff RC, Johnson MP, Huang XM, Nichols DE. Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. J Med Chem. 1992 Jan 24; 35(2):203-11.

Johnson MP, Huang XM, Nichols DE. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav. 1991 Dec; 40(4):915-22.

Huang XM, Johnson MP, Nichols DE. Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). Eur J Pharmacol. 1991 Jul 23; 200(1):187-90.

Nichols DE, Snyder SE, Oberlender R, Johnson MP, Huang XM. 2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. J Med Chem. 1991 Jan; 34(1):276-81.

Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE. Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. Eur J Pharmacol. 1990 Nov 20; 191(1):1-10.


Latest Updates

08/13/2018 - 14:41
08/01/2018 - 15:48
07/16/2018 - 13:43

Philanthropic Support

We gratefully acknowledge generous support for radiology research at NYU Langone Medical Center from:
• The Big George Foundation
• Raymond and Beverly Sackler
• Bernard and Irene Schwartz

Go to top